Image Source: Getty Images
Continue Reading Below
Shares of the clinical-stage biotechRigel Pharmaceuticals (NASDAQ: RIGL) gained more than 34% in the month of August, according toS&P Global Market Intelligence.
The company's stock exploded higher on the next to last day in August on the announcement that itsoral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, hit the mark in the first of two late-stage studies assessing its efficacy against the bleeding disorder known as adult chronic/persistent immune thrombocytopenia (ITP). Specifically, the company reported that patients treated withfostamatinib exhibited a statistically significant stabilization in bloodplatelet levels, compared to those receiving a placebo (p=0.0261). What this means is that fostamatinib shouldimprove an ITP patient's ability to form blood clots and avoid potentially life-threatening bouts of severe bleeding.
The Street hasfostamatinib's peak sales currently pegged at around $360 million as a standard treatment for ITP. If that line holds, Rigel's stock would seem to be severely undervalued right now in light of its rather meager market cap of less than $330 million. After all, it's not uncommon for clinical-stage biotechs to trade somewhere around 3-5 times the peak sales potential of their lead product candidates.
Rigel expects to unveil the results fromfostamatinib's second late-stage trial in either October or November of this year. If this trial reports similar results, the company plans on filing forfostamatinib's regulatory approval with the U.S. Food and Drug Administration in thefirst quarter of 2017.
Before investors get too excited, however, it's important to understand why the market hasn't built in much of a premium (if any) for this emerging clinical-stage biotech just yet. First off, Rigel is a tiny company with little experience in handling a regulatory filing. So, even if this second trial goes as planned, there's no guarantee the company will be able to navigate the regulatory review process in a timely and efficient manner. And that leads into the second problem facing Rigel's shareholders.
Per its latest financial reports, the biotech's cash position in relation to its current burn rate would seem to necessitate a capital raise within the next year, and that's not even accounting for the additional costs associated with marketing a new drug.
All told, Rigel comes across as a compelling watch list candidate right now based on fostamatinib's clinical progress and commercial potential. But the company still faces some critical hurdles that make it a tad too risky for my taste.
A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.